NYSE:PFE News 24 October 2025

Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Background: Novo vs. Pfizer in the Weight-Loss Drug Race The fight for Metsera is driven by fierce competition in GLP-1 obesity drugs. Novo Nordisk is the maker of Wegovy/Ozempic, and Eli Lilly’s drugs recently overtook Wegovy in US market share

4 November 2025

Pfizer’s Q3 Shocker: Earnings Beat, Outlook Raised, and a $7 Billion Obesity Drug Gambit

Q3 Earnings Beat and Raised Outlook Pfizer delivered a positive surprise in Q3 2025, topping earnings and revenue expectations even as its overall results declined from a year ago. Adjusted earnings per share came in at $0.87, comfortably above consensus

4 November 2025

Drug Development · Earnings Reports · Market Analysis · NYSE:PFE · Obesity Treatments · Pharmaceuticals

Nasdaq Stumbles as Fed Jitters Mount, Intel Soars, Tariffs Rattle Tech Markets

AI Rally Hits Speed Bump as Futures Fall – Key Facts Before the Nov. 4 Market Open

U.S. Futures Slide as Tech Rally Stalls Stock index futures are firmly in the red before the opening bell, indicating Wall Street will give back some of Monday’s gains. S&P 500 futures are down roughly 0.9% and Nasdaq 100 futures

4 November 2025

Artificial Intelligence · Financial Trends · Investment News · Market Analysis · NASDAQ:AMD · NASDAQ:AMGN · NASDAQ:AMZN · NASDAQ:SHOP · NASDAQ:SPOT · NYSE:BP · NYSE:PFE · NYSE:PLTR · NYSE:RACE · NYSE:UBER · Stock Market

Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Stock Price and Recent Performance Pfizer’s stock has languished in 2025 despite a rising broader market. At ~$24.65, PFE is roughly flat since January and far below its 2021 peak (~$50) sharewise.com. In the past three years, the shares have

3 November 2025

Dividends · Investment Strategies · Market Outlook · NYSE:PFE · Pharmaceuticals · Stocks

Pfizer Stock Surges on Trump Deal & Obesity Drug Drama – Is a Comeback Coming?

Company Background & Significance Founded in 1849, Pfizer Inc. has grown into a pillar of the pharmaceutical industry, known for landmark drugs and vaccines. From breakthrough treatments like Lipitor (cholesterol) and Viagra (ED), to its 2020 partnership with BioNTech delivering

2 November 2025

Health Industry · Investing · Market News · NYSE:PFE · Pharmaceuticals · Stocks

Pfizer Stock Surges on Trump’s Drug Price Deal & $7B Obesity Gamble – Is This the Comeback Investors Hoped For?

Technical Analysis – Levels to Watch From a technical perspective, Pfizer’s stock has been basing in the low-to-mid $20s and has yet to break out of its longer-term downtrend. The 52-week range is roughly $20.92 to $30.43 ts2.tech, and the

1 November 2025

Business News · Healthcare Investments · NYSE:PFE · Pfizer · Pharma Industry · Stock Market

Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk’s $9B Shock Bid Snatches US Weight-Loss Biotech from Pfizer – Stocks React Big

Bidding War Ignites for Obesity Biotech Novo’s takeover push marks a sudden escalation in the weight-loss drug wars. The Danish company – maker of Wegovy and Ozempic – broke ranks on Oct. 30 by notifying Metsera’s board of its superior

31 October 2025

Biotech Industry · Mergers & Acquisitions · NASDAQ:MTSR · NYSE:NVO · NYSE:PFE · Pharma News · Stock Market · Weight Loss

Pfizer Stock Soars: Trump’s Drug-Price Deal and $7B Weight-Loss Bet Spark Rally

Stock Price & Recent Performance Pfizer’s stock has been rangebound in the low-to-mid $20s for much of 2025. By late September, PFE traded around $23.60 – about 9% below its price a year earlier ts2.tech – as investors grappled with

30 October 2025

Drug Pricing · Investment News · NYSE:PFE · Pharmaceuticals · Stock Market · Trump Administration

Metsera Stock Skyrockets as Pfizer-Novo Clash in $9B Bidding War

Bidding War Sends Metsera Shares Higher Metsera’s share price has been on a roller-coaster amid takeover speculation. In late September, Pfizer agreed to buy Metsera for $47.50 per share in cash (about $4.9B) plus up to $22.50 in contingent payments

30 October 2025

Business · Investing · Mergers & Acquisitions · NASDAQ:MTSR · NYSE:NVO · NYSE:PFE · Pharma News · Stock Market

Novo Nordisk hijacks Pfizer’s Metsera deal with a $9B bid – obesity-drug war heats up

Novo’s counter-offer details Novo Nordisk’s proposal is unsolicited, meaning Metsera’s board and shareholders will now review it against Pfizer’s agreement. Novo emphasizes that Metsera’s experimental therapies would be “complementary” to its own obesity portfolio reuters.com. According to MarketScreener (Dow Jones

30 October 2025

Biotechnology · Industry News · Mergers & Acquisitions · NYSE:NVO · NYSE:PFE · Obesity Drugs · Pharmaceuticals

Pfizer Stock Surges 15% on Trump’s Pricing Pact & $7.3B Obesity Deal – Can the Rally Last?

Pfizer (PFE) Stock Rebounds on Trump Drug Deal & Obesity Gamble – Can the Rally Last?

PFE Stock Price and Recent Performance Pfizer’s stock has endured a rough 2025, trading in the low-to-mid $20s for much of the year and touching multi-year lows. By late September, PFE was around $23.60 – down ~9% year-to-date and ~18%

27 October 2025

Business News · Health Industry · Investing · NYSE:PFE · Pharmaceuticals · Stock Market

U.S. Stocks Rally as Shutdown Fears Fade – Markets Hit Fresh Records

Wall Street Explodes: Dow Jones Jumps 400 Points as Inflation Cools – Tech Stocks Lead, Fed Cuts Expected

Record Highs on All Fronts, Led by Tech Stocks Friday’s broad rally sent all major U.S. indexes to fresh highs. The Dow’s 400‑point gain topped the largest single‑day jump of 2025, while the S&P 500 and Nasdaq also closed at

24 October 2025

Economic News · Federal Reserve · Inflation · NASDAQ:AAPL · NASDAQ:AMD · NASDAQ:INTC · NASDAQ:MSFT · NASDAQ:MU · NASDAQ:NVDA · NYSE:BA · NYSE:CVX · NYSE:KO · NYSE:PFE · NYSE:XOM · Stock Market · Tech Stocks

NYSE:PFE News 24 October 2025 - 4 November 2025